# IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Source: https://onco.cc/trials/nct05987332/  
OnCo record `nct05987332` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Darovasertib, Crizotinib, Pembrolizumab in melanoma and uveal melanoma, run by IDEAYA Biosciences, active and no longer recruiting.

## Summary

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma is a phase 2/3 interventional study registered as NCT05987332 by IDEAYA Biosciences, with 420 participants planned, started 2023-10-31 and due to reach its primary completion in 2027-01-15. Interventions recorded: IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab. Conditions listed: Metastatic Uveal Melanoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05987332
- Phase: 2/3
- Setting: IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator's Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2)
- Sponsor: IDEAYA Biosciences
- Enrolled: 420

## Sources

- ClinicalTrials.gov NCT05987332: https://clinicaltrials.gov/study/NCT05987332

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- drugs: [Crizotinib](https://onco.cc/drugs/crizotinib/), [Dacarbazine](https://onco.cc/drugs/dacarbazine/), [Darovasertib](https://onco.cc/drugs/darovasertib/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [IDEAYA Biosciences](https://onco.cc/companies/ideaya-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct05987332.json